TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) changed the standard care of patients with lung squamous cell carcinoma (LUSC). It is an urgent need to precisely predict the population’s response to ICIs. The aim of the study was to explore novel biomarkers for LUSC immunotherapy and the potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jiangyong, Fan, Zaiwen, Zhou, Zhipeng, Zhang, Ping, Bai, Jing, Li, Xu, Tang, Min, Fan, Nannan, Wu, Xiaonan, Nie, Xin, Chen, Xiaoyan, Ma, Di, Chen, Xi, Cui, Liang, Xia, Xuefeng, Yang, Ling, Yi, Xin, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320428/
https://www.ncbi.nlm.nih.gov/pubmed/35884443
http://dx.doi.org/10.3390/cancers14143382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320428/
https://www.ncbi.nlm.nih.gov/pubmed/35884443
http://dx.doi.org/10.3390/cancers14143382

Ejemplares similares